Search

everythinglearnresearchcommunity

for

Search:↓

The user is experiencing hair loss, initially diagnosed as Telogen Effluvium due to stress, but is concerned it might be Androgenetic Alopecia (AGA). A suggestion was made to consider using Minoxidil or Finasteride if the condition worsens.

The user experienced anxiety and heart pounding from oral minoxidil, despite its effectiveness, and switched back to topical minoxidil. After managing anxiety, they found oral minoxidil more effective, but side effects differ for each person.

The user has scheduled a hair transplant after stabilizing hair loss with finasteride and minoxidil, considering additional dermarolling. They are advised to use 2500-3000 grafts conservatively for temple filling without lowering the hairline too much.

A user started taking 1mg of finasteride daily but experienced anxiety and brain fog, considering reducing the dose to 0.5mg to adjust. They seek advice on whether this change could help manage side effects and hair shedding.

HMI-115 is a new drug developed by Bioinvent and licensed by Bayer, with mixed opinions on its potential effectiveness. Some users are skeptical and prefer proven treatments like Minoxidil, finasteride, and RU58841.

The user is anxious about potential side effects of finasteride, particularly PFS, and is considering reinstating it for hair loss treatment. They experienced anxiety-induced side effects previously and are seeking advice on overcoming their fear of restarting finasteride.

A user is concerned about low testosterone while using finasteride 0.625mg MWF and considers ashwagandha for stress. Others suggest exercise, magnesium, and not worrying about testosterone levels if no significant side effects are felt.

A 21-year-old male, 13 months into hair loss treatment, reports increased hair fall despite using Dutasteride, oral Minoxidil, vitamins, and specialized shampoos. He questions the impact of anxiety and depression on hair fall and is hesitant to seek therapy.

The user stopped taking Finasteride after 8 years to try for kids but noticed hair loss and reduced anxiety. They are considering resuming Finasteride to prevent further hair loss.

A Phase 1 update for the HMI 115 clinical trial, which involves 16 participants and is expected to end in July 2023; as well as changes to the recruitment process, including treatment protocols with Minoxidil, Finasteride, and RU58841.

The user began experiencing hair loss a few years ago at age 22 and is a diffuse thinner with a Norwood scale rating of 2. They have a naturally athletic build and gain muscle easily, with a hairy chest and stomach.

The user is dealing with early hair loss and is using a serum with Redensyl, multivitamins, and plans to add minoxidil. They seek advice on maintaining a positive mindset and improving hair health through lifestyle changes.

The conversation discusses HMI-115, a potential cure for hair loss. Users share mixed opinions, with some expressing skepticism and others sharing anecdotal evidence of its effectiveness, including photos of significant hair regrowth from a trial participant.

Hope Medicine received a $28M investment for HMI-115, a monoclonal antibody in phase II trials for treating androgenetic alopecia. Some users are skeptical about its effectiveness, while others find the investment and trial results encouraging.

A 24-year-old woman being diagnosed with androgenic alopecia (AGA) who is scared and confused about her hair loss, and the treatment options of Minoxidil, finasteride, RU58841, spironolactone, and possibly a biopsy.

Hope Medicine's announcement of the HMI-115 Phase II clinical trial for androgenetic alopecia in China; other related trials have been conducted or are ongoing in different countries, including Australia, US, and Europe. There is speculation that the product may be accepted across borders without additional testing.

The user is concerned about the quick prescription process for hair loss treatments like Minoxidil and Finasteride through HIMs, questioning the lack of a thorough evaluation. Another user reassures that such practices are common, emphasizing the effectiveness and low risk of these treatments, and suggests monitoring personal response to the medication.

Finasteride helped users feel better about hair loss, with some experiencing positive changes in confidence and reduced anxiety. Despite initial concerns, users reported satisfaction with the treatment over several months.

A user ordered H&W's 1.25% Topical Finasteride and is curious about others' experiences and side effects. Another user asked about availability in the US.

The post discusses a phase 2 trial for HMI-115, a hair loss treatment, in China, specifically seeking volunteers aged 18-65 with Norwood 3 vertex, 4, and 5 hair loss. The conversation includes questions about the specific recruitment criteria and how to volunteer.

Hair loss can cause significant stress and anxiety, leading individuals to try various treatments like microneedling, hair transplants, and lifestyle changes. Some people find peace by accepting hair loss and focusing on other aspects of life, while others experience ongoing distress.

The post discusses the completion of the HMI-115 Australian Phase 1 Trial for hair loss treatment. The user speculates about the potential early release of the trial results.

The potential availability of a new hair loss treatment called HMI-115, which has shown promising results in experiments on monkeys but is not yet available to the public. Replies cautioned against using unproven substances from shady labs.

A user experienced persistent headaches after a stressful week and questioned if 0.25mg finasteride could be the cause, despite using minoxidil for two years. Another user suggested stress is likely the main factor, not the medication, and advised consulting a healthcare provider if headaches persist.

The conversation discusses HMI 115, a new hair loss treatment with promising results, showing a significant increase in hair density after two months. Some users are skeptical, while others are hopeful for its release and potential affordability.

A 24-year-old male experiencing diffused thinning discusses his DHT levels and hair density issues. He has not used finasteride or dutasteride and is considering AR inhibitors.

The user has been using finasteride, dutasteride, and RU58841 for hair loss without success and feels extremely uncomfortable with their appearance, including being bald and short. They express deep unhappiness and social isolation. Suggestions from others include adopting stoicism, focusing on personal development, considering a hair system, improving fashion, working out, and seeking therapy for mental health.

A 24-year-old is struggling with severe depression and anxiety due to hair loss, despite using dutasteride and oral minoxidil for two years. They are advised to consider shaving their head, exploring wigs or hair systems, and focusing on other aspects of life like health, relationships, and career.

Hope Medicine's HMI-115 is expected to be released in 2027, with phase 3 trials currently recruiting. Concerns include the safety of targeting prolactin and the potential cost of the treatment.

The user switched from topical to oral minoxidil (5mg daily) a year ago, saw no improvement, and experienced chest pain and trouble sleeping after stopping. They are considering whether to resume and taper the dosage due to stress and anxiety.